Does the media prefer BMEA or FENC?

In the previous week, Adherex Technologies had 3 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Adherex Technologies and 1 mentions for Biomea Fusion. Adherex Technologies' average media sentiment score of 0.45 beat Biomea Fusion's score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BMEA or UPB more profitable?

Biomea Fusion has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Upstream Bio -4,718.96% -43.82% -42.27%

Does the media favor BMEA or UPB?

In the previous week, Upstream Bio had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Upstream Bio and 1 mentions for Biomea Fusion. Upstream Bio's average media sentiment score of 0.90 beat Biomea Fusion's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, BMEA or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.68 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A

Is BMEA or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -69.61% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Rocket Pharmaceuticals N/A -69.61% -58.63%

Does the media prefer BMEA or RCKT?

In the previous week, Rocket Pharmaceuticals had 4 more articles in the media than Biomea Fusion. MarketBeat recorded 5 mentions for Rocket Pharmaceuticals and 1 mentions for Biomea Fusion. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Biomea Fusion's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ABEO or BMEA more profitable?

Abeona Therapeutics' return on equity of -53.98% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Abeona Therapeutics N/A -53.98% -38.52% Biomea Fusion N/A -265.37% -103.96%

Does the media prefer ABEO or BMEA?

In the previous week, Abeona Therapeutics had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Biomea Fusion. Abeona Therapeutics' average media sentiment score of 0.01 beat Biomea Fusion's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PALI or BMEA more profitable?

Palisade Bio's return on equity of -36.79% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Biomea Fusion N/A -265.37% -103.96%

Does the media prefer PALI or BMEA?

In the previous week, Palisade Bio had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Palisade Bio and 1 mentions for Biomea Fusion. Palisade Bio's average media sentiment score of 0.84 beat Biomea Fusion's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biomea Fusion (BMEA) Competitors

$1.23 +0.03 (+2.50%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.25 +0.02 (+1.22%)

As of 07:02 AM Eastern

Compare

BMEA vs. FENC, UPB, RCKT, ABEO, and PALI

Should you buy Biomea Fusion stock or one of its competitors? MarketBeat compares Biomea Fusion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomea Fusion include Adherex Technologies (FENC), Upstream Bio (UPB), Rocket Pharmaceuticals (RCKT), Abeona Therapeutics (ABEO), and Palisade Bio (PALI).

How does Biomea Fusion compare to Adherex Technologies?

Biomea Fusion (NASDAQ:BMEA) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Biomea Fusion has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Biomea Fusion has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Biomea Fusion currently has a consensus price target of $8.50, suggesting a potential upside of 591.06%. Adherex Technologies has a consensus price target of $15.40, suggesting a potential upside of 52.32%. Given Biomea Fusion's higher probable upside, equities research analysts plainly believe Biomea Fusion is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Adherex Technologies has higher revenue and earnings than Biomea Fusion. Adherex Technologies is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Adherex Technologies	$44.64M	7.93	-$9.74M	-$0.29	N/A

In the previous week, Adherex Technologies had 3 more articles in the media than Biomea Fusion. MarketBeat recorded 4 mentions for Adherex Technologies and 1 mentions for Biomea Fusion. Adherex Technologies' average media sentiment score of 0.45 beat Biomea Fusion's score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Adherex Technologies beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to Upstream Bio?

Biomea Fusion (NASDAQ:BMEA) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Biomea Fusion has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

96.7% of Biomea Fusion shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Biomea Fusion has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

Biomea Fusion has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Upstream Bio	$2.85M	129.65	-$143.44M	-$2.91	N/A

In the previous week, Upstream Bio had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Upstream Bio and 1 mentions for Biomea Fusion. Upstream Bio's average media sentiment score of 0.90 beat Biomea Fusion's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion presently has a consensus target price of $8.50, suggesting a potential upside of 591.06%. Upstream Bio has a consensus target price of $33.17, suggesting a potential upside of 388.46%. Given Biomea Fusion's stronger consensus rating and higher possible upside, research analysts clearly believe Biomea Fusion is more favorable than Upstream Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Biomea Fusion beats Upstream Bio on 8 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to Rocket Pharmaceuticals?

Biomea Fusion (NASDAQ:BMEA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 591.06%. Rocket Pharmaceuticals has a consensus target price of $8.71, indicating a potential upside of 153.32%. Given Biomea Fusion's stronger consensus rating and higher possible upside, research analysts plainly believe Biomea Fusion is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Rocket Pharmaceuticals' return on equity of -69.61% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biomea Fusion has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

In the previous week, Rocket Pharmaceuticals had 4 more articles in the media than Biomea Fusion. MarketBeat recorded 5 mentions for Rocket Pharmaceuticals and 1 mentions for Biomea Fusion. Rocket Pharmaceuticals' average media sentiment score of 0.45 beat Biomea Fusion's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rocket Pharmaceuticals beats Biomea Fusion on 8 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Abeona Therapeutics' return on equity of -53.98% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Biomea Fusion	N/A	-265.37%	-103.96%

Abeona Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 178.59%. Biomea Fusion has a consensus price target of $8.50, indicating a potential upside of 591.06%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 7.1% of Abeona Therapeutics shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Abeona Therapeutics has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	66.78	$71.18M	$0.97	7.03
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

In the previous week, Abeona Therapeutics had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Abeona Therapeutics and 1 mentions for Biomea Fusion. Abeona Therapeutics' average media sentiment score of 0.01 beat Biomea Fusion's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abeona Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Abeona Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, suggesting that its stock price is 128% less volatile than the broader market.

Summary

Abeona Therapeutics beats Biomea Fusion on 9 of the 14 factors compared between the two stocks.

How does Biomea Fusion compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Palisade Bio had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 2 mentions for Palisade Bio and 1 mentions for Biomea Fusion. Palisade Bio's average media sentiment score of 0.84 beat Biomea Fusion's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palisade Bio has higher revenue and earnings than Biomea Fusion. Palisade Bio is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,437.24	-$16.78M	-$1.01	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 10.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Palisade Bio presently has a consensus target price of $9.00, indicating a potential upside of 334.78%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 591.06%. Given Biomea Fusion's higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Palisade Bio's return on equity of -36.79% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Biomea Fusion	N/A	-265.37%	-103.96%

Palisade Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market.

Summary

Palisade Bio beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMEA vs. The Competition

Export

Metric	Biomea Fusion	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$86.76M	$3.52B	$6.83B	$12.77B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	-1.81	7.32	279.15	25.53
Price / Sales	N/A	1,269.15	587.36	92.31
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	2.93	17.36	13.06	6.11
Net Income	-$61.80M	-$12.52M	$3.48B	$347.58M
7 Day Performance	0.82%	3.64%	3.38%	4.91%
1 Month Performance	-12.77%	-5.38%	-2.81%	-2.06%
1 Year Performance	-22.15%	49.44%	73.07%	21.03%

Biomea Fusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMEA Biomea Fusion	1.8569 of 5 stars	$1.23 +2.5%	$8.50 +591.1%	-23.6%	$86.76M	N/A	N/A	50
FENC Adherex Technologies	3.9241 of 5 stars	$10.21 +2.2%	$15.40 +50.8%	+21.5%	$349.99M	$44.64M	N/A	10	News Coverage
UPB Upstream Bio	2.6205 of 5 stars	$6.40 -0.2%	$33.17 +418.2%	-56.5%	$348.83M	$2.85M	N/A	38	Positive News Analyst Forecast
RCKT Rocket Pharmaceuticals	2.7715 of 5 stars	$3.25 +1.9%	$8.71 +168.1%	+12.1%	$348.33M	N/A	N/A	240	Upcoming Earnings
ABEO Abeona Therapeutics	3.4003 of 5 stars	$6.13 +1.3%	$19.00 +210.0%	+6.2%	$344.82M	$5.82M	6.32	90	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMEA) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Competitors

BMEA vs. FENC, UPB, RCKT, ABEO, and PALI

How does Biomea Fusion compare to Adherex Technologies?

Summary

How does Biomea Fusion compare to Upstream Bio?

Summary

How does Biomea Fusion compare to Rocket Pharmaceuticals?

Summary

How does Biomea Fusion compare to Abeona Therapeutics?

Summary

How does Biomea Fusion compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomea Fusion (BMEA) Competitors

BMEA vs. FENC, UPB, RCKT, ABEO, and PALI

How does Biomea Fusion compare to Adherex Technologies?

Is BMEA or FENC more profitable?

Which has more volatility & risk, BMEA or FENC?

Do insiders & institutionals have more ownership in BMEA or FENC?

Do analysts rate BMEA or FENC?

Which has better earnings & valuation, BMEA or FENC?

Does the media prefer BMEA or FENC?

Summary

How does Biomea Fusion compare to Upstream Bio?

Is BMEA or UPB more profitable?

Do insiders and institutionals have more ownership in BMEA or UPB?

Which has more volatility and risk, BMEA or UPB?

Which has higher valuation & earnings, BMEA or UPB?

Does the media favor BMEA or UPB?

Do analysts recommend BMEA or UPB?

Summary

How does Biomea Fusion compare to Rocket Pharmaceuticals?

Do analysts prefer BMEA or RCKT?

Is BMEA or RCKT more profitable?

Do insiders & institutionals hold more shares of BMEA or RCKT?

Which has more volatility and risk, BMEA or RCKT?

Which has preferable valuation and earnings, BMEA or RCKT?

Does the media prefer BMEA or RCKT?

Summary

How does Biomea Fusion compare to Abeona Therapeutics?

Is ABEO or BMEA more profitable?

Do analysts recommend ABEO or BMEA?

Do insiders and institutionals hold more shares of ABEO or BMEA?

Which has preferable valuation & earnings, ABEO or BMEA?

Does the media prefer ABEO or BMEA?

Which has more risk and volatility, ABEO or BMEA?

Summary

How does Biomea Fusion compare to Palisade Bio?

Does the media prefer PALI or BMEA?

Which has stronger earnings and valuation, PALI or BMEA?

Do insiders & institutionals hold more shares of PALI or BMEA?

Do analysts recommend PALI or BMEA?

Is PALI or BMEA more profitable?

Which has more risk & volatility, PALI or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools